Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leuprorelin
- Development stage
- Phase 3
- Lead developer
- Novosis
- Modality
- Peptides
- Administration
- Subcutaneous, Implant
01
Overview
Novosis leuprorelin is a 10.72 mg biodegradable subcutaneous implant formulation of the gonadotropin-releasing hormone (GnRH) agonist leuprorelin (also known as leuprolide). Developed by Novosis AG, this sustained-release formulation is designed to provide therapeutic testosterone suppression over a 12-week period for the treatment of advanced prostate cancer. As a GnRH agonist, it initially stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), but continuous exposure leads to GnRH receptor downregulation. This results in a profound reduction in LH and FSH secretion, subsequently lowering serum testosterone to castrate levels, which inhibits the growth of hormone-dependent prostate cancer cells. In Phase III clinical trials, the Novosis implant demonstrated non-inferiority to established leuprorelin formulations like Trenantone.
- Other names
- Novosis leuprorelin
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)LH (Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1)
Beyond the preview
Go deeper on leuprorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leuprorelin.